Denali Therapeutics (DNLI) FCF Margin (2018 - 2023)
Denali Therapeutics (DNLI) reported FCF Margin of 7058.48% for Q3 2023, up 2723282.0% year-over-year from N/an in Q3 2022, and down 17838.85% quarter-over-quarter from 39.35% in Q2 2023.
Denali Therapeutics (DNLI) FCF Margin (2018 - 2023) Analysis & Trends
Denali Therapeutics (DNLI) has 6 years of FCF Margin data on file, last reported at 7058.48% in Q3 2023.
- FCF Margin for Q3 2023 came in at 7058.48%, up 2723282.0% year-over-year; the trailing twelve-month figure through Jun 2024 was 31736.31% (down 3164650.0% YoY), and the FY2023 annual result was 112.22%, up 713263.0% from the prior year.
- FCF Margin fell to 7058.48% in Q3 2023 per DNLI's latest filing, from 39.35% in the prior quarter.
- Over five years, FCF Margin peaked at 161.84% in Q4 2020 and troughed at 5024000.0% in Q1 2021.
- A 5-year average of 299484.53% and a median of 742.48% in 2020 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2021 and 2022: FCF Margin slumped 491751731 bps in 2021, then soared 502382862 bps in 2022.
- A 5-year view of FCF Margin shows it stood at 124040.62% in 2019, then jumped by 100 bps to 161.84% in 2020, then sank by 465 bps to 591.06% in 2021, then decreased by 3 bps to 611.43% in 2022, then tumbled by 1054 bps to 7058.48% in 2023.
- Business Quant data shows DNLI's FCF Margin at 7058.48% in Q3 2023, 39.35% in Q2 2023, and 184.62% in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Denali Therapeutics | 4.35 Bn | 4.35 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -7,058.48% |
| Jun 30, 2023 | -39.35% |
| Mar 31, 2023 | -184.62% |
| Dec 31, 2022 | -611.43% |
| Sep 30, 2022 | -34,291.30% |
| Jun 30, 2022 | -94.74% |
| Mar 31, 2022 | -171.38% |
| Dec 31, 2021 | -591.06% |
| Sep 30, 2021 | -780.21% |
| Jun 30, 2021 | -363.00% |
| Mar 31, 2021 | -5,024,000.00% |
| Dec 31, 2020 | 161.84% |
| Sep 30, 2020 | -36,240.00% |
| Jun 30, 2020 | -726.53% |
| Mar 31, 2020 | -106,482.69% |
| Sep 30, 2019 | -124,040.63% |
| Jun 30, 2019 | -54,449.49% |
| Mar 31, 2019 | -758.43% |
| Dec 31, 2018 | 71.51% |
| Sep 30, 2018 | -2,824.27% |